Rare Diseases Clinical Trials Update: Week 45, 2026

Published November 6, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

This ongoing study looks at how three different treatments—eteplirsen, golodirsen, and casimersen—affect people living with Duchenne Muscular Dystrophy over a long period. By observing patients who are already using these therapies, researchers hope to better understand their impact on disease progression and daily life. The results could help doctors and families make more informed choices about managing this challenging condition.

A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)

This Phase 3 trial is testing the safety and effectiveness of N-acetyl-L-leucine in children and adults with Ataxia-Telangiectasia, a rare genetic disorder that affects movement and the immune system. If the treatment proves helpful, it may improve symptoms and quality of life for those living with this condition. The study involves 60 participants across several countries and is currently active but not enrolling new patients.

A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia

This upcoming Phase 3 trial will test a drug named navepegritide in young people with hypochondroplasia, a rare growth disorder causing shorter stature and other challenges. The study aims to see if the drug can support better growth and development in affected children. It plans to enroll 81 participants but has not started recruiting yet.

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

This Phase 2 study is exploring a stem cell transplant method designed to treat inherited metabolic disorders and severe osteopetrosis, conditions that affect bone and metabolism. The approach includes careful drug monitoring to improve transplant success and reduce risks. Conducted at a single site in the United States, the trial is active but not currently enrolling new patients.

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

This Phase 2 trial is testing andecaliximab, an antibody treatment, in people living with fibrodysplasia ossificans progressiva, a rare disease that causes painful and abnormal bone growth. The treatment aims to reduce flare-ups and improve mobility. The study is currently enrolling about 92 participants in the United States.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.